Stay updated on Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.

Latest updates to the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedLocations information has been reorganized into a single Locations section listing all participating states (Alabama, Colorado, Illinois, Kansas, Massachusetts, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Texas), replacing the prior per-state location blocks.SummaryDifference1%

- Check52 days agoChange DetectedRevision: v3.3.2 added and v3.2.0 removed. No content changes to study data are involved.SummaryDifference0.0%

- Check59 days agoChange DetectedThe government funding status notice on the page has been removed.SummaryDifference0.3%

- Check74 days agoChange DetectedNo significant changes to core study information (eligibility criteria, outcomes, or locations); only minor formatting and layout adjustments were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check102 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

Stay in the know with updates to Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.